Klinik und Poliklinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie -	Tel. (0251) 83-47742 Fax: (0251) 83-47828 e-mail: paedonc@uni-muenster.de www: klinikum.uni-muenster.de/institute/paedonc
Albert-Schweitzer-Str. 33 48149 Münster Direktor: Prof. Dr. Med. Heribert Jürgens
Forschungsschwerpunkte 2003 - 2004    zurück    weiter

Klinische Studien Infektiologisches Forschungsprogramm   Übergeordnetes Ziel des 2002 initiierten Infektiologischen Forschungsprogramms ist die Entwicklung neuer Strategien gegen Infektionen durch Pilze und Viren. Der Schwerpunkt des Programms liegt auf der klinischen und präklinischen Entwicklung neuer antimikrobieller Substanzen, der Dosisfindung und Evaluation von Sicherheit und Verträglichkeit von antimikrobiellen Substanzen bei pädiatrischen Patienten mit Abwehrschwäche, sowie Untersuchungen zur Epidemiologie und Resistenzentwicklung in vitro. Klinische Studien: A.H.Groll Principal Investigator: A Phase II study investigating the pharmacokinetics, safety and tolerance of caspofungin alone and in combination with liposomal amphotericin B in patients with allogeneic hematopoietic stem cell transplantation (laufende klinische Studie) Caspofungin in immunocompromised patients without therapeutic alternative: A multicenter survey of the DGPI/GPOH working party on Infections in Pediatric Cancer Patients (Probandeneinschluss 2004 abgeschlossen) Compliance in der antiinfektiven Supportivtherapie pädiatrisch-onkologischer Patienten ((laufende epidemiologische Studie) A.H. Groll Principal Investigator for Germany: An open-label, intravenous to oral switch, multiple-dose, multi-centre study to investigate the pharmacokinetics, safety and tolerability of voriconazole in hospitalized children aged 2 to ‹12 years who require treatment for the prevention of systemic fungal infections (Probandeneinschluss 2004 abgeschlossen) A multicenter, double-blind, randomized comparative study to evaluate the safety, tolerability and efficacy of caspofungin versus amphotericin B liposome for injection as empirical therapy in pediatric patients with persistent fever and neutropenia (laufende klinische Studie) A.H. Groll Co-ordinator for Germany: Zygomycoses in Europe. Survey of the European Confederation for Medical Mycology (ECMM) (laufende epidemiologische Studie) Präklinische Studien: Compartimentalized intrapulmonary disposition of four licensed amphotericin B formulations in noninfected rabbits (in Kooperation mit Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA; abgeschlossen) Differential intrapulmonary disposition of voriconazole and liposomal amphotericin B in noninfected rabbits (in Kooperation mit Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA; abgeschlossen) Efficacy, safety, and plasma pharmacokinetics of PLD-118, a novel inhibitor of Candida Isoleucyl tRNA synthase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits (in Kooperation mit Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA; abgeschlossen) Compartmental plasma pharmacokinetics and tissue distribution of the antifungal beta-amino acid PLD-118 in noninfected rabbits (in Kooperation mit Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA; abgeschlossen) Beteiligte Wissenschaftler: Priv. Doz. Dr. med. Andreas H. Groll; Hedwig Kolve Veröffentlichungen: Belohradsky BH, Heininger U, Kreth W, Roos R, Scholz H (eds.).Futuramed Verlag, Muenchen, 2003: pp. 857-876 Gea Banacloche J,Groll AH, Walsh TJ. Fungal infections in neutropenic patients. In Oxford Textbook of Clinical Mycology. Dismukes WE, Pappas PG, Sobel JD (eds.). Oxford University Press, New York, NY, 2003: pp. 427-455 Groll AH. Antimicrobial therapy of invasive fungal infections in patients with cancer -current approaches and future strategies. Business Briefing: European Pharmacotherapy. Business Briefings Ltd., London, UK, 2003: pp.118-121. Groll AH, Baumann-Koehler M, Storkebaum B, Kuehn J, Juergens H, Vormoor J. Durable Clearance of Hepatitis B Virus following Allogeneic Blood Stem Cell Transplantation by Adoptive Immunity Transfer and Antiviral Chemotherapy. Pediatr Infect Dis J 22: 753-755, 2003 Groll AH, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical Pharmacology of antifungal compounds. Infect Dis Clin North Amer 17: 159-191, 2003 Groll AH, Mickiene D, Petraitis V, Petraitiene R, Alfaro RM, King CH, Piscitelli SC, Walsh TJ. Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits. Antimicrob Agents Chemother 47: 3917-3925, 2003 Groll AH, Walsh TJ. Fungal infections in pediatric patient. In: Clinical Mycology. Anaissie EJ, McGinnis MR, Pfaller MA (eds); Churchill Livingstone, Philadelphia, PA, 2003: pp. 417-442 Groll AH, Walsh TJ. Recent developments in epidemiology and management of invasive fungal infections. In Lazarus HM, Laughlin MJ: Allogeneic stem cell transplantation. Clinical Research and Practice. Humana Press, Totowa, NJ, 2003: pp. 191-213 Groll AH, Walsh TJ. Antifungal Agents. In Feigin, Cherry, Demmler, and Kaplan: Textbook of Pediatric Infectious Diseases, 5th edition. WB Saunders, Philadelphia, PA, 2003: pp. 3075-3108 Groll AH, Walsh TJ. Antifungal drugs. In: Side effects of drugs, Annual 26, Chapter 27. Aronson JK, van Boxtel CJ (eds.). Elsevier Science, Amsterdam, 2003: pp. 302-314 Groll AH, Walsh TJ. Cell wall synthesis inhibitors. In Oxford Textbook of Clinical Mycology. Dismukes WE, Pappas PG, Sobel JD (eds.). Oxford University Press, New York, NY, 2003: pp. 88-103 Liese J, Belohradsky BH, Graubner U,Groll AH, Haas A, Mueller FM. Aspergillus-Infektionen. In: DGPI Handbuch -Infektionen bei Kindern und Jugendlichen, 4. Auflage. Belohradsky BH, Heininger U, Kreth W, Roos R, Scholz H (eds.).Futuramed Verlag, Muenchen, 2003: pp. 203-208 Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, Sein T,Groll AH, Bacher J, Avila NA, Walsh TJ. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and echinocandin. J Infect Dis 2003; 187: 1834-1843 Boucher H, Chiou CC,Groll AH, Walsh TJ. Emerging antifungal therapeutics. Drugs 64: 1997-2020, 2004 Graubner UB, Schmid I, Belohradsky BH,Groll AH, Lehrnbecher T, Mueller FM, Ritter J, Simon A, Weiss M: Infektionen bei Granulozytopenie. In: DGPI Handbuch -Infektionen bei Kindern und Jugendlichen, 4. Auflage. Schloesser RL, Schaefer V,Groll AH. Fatal transplacental infection with nontyphoidal Salmonella. Scand J Infect Dis 36: 773-774, 2004 Groll AH, Kolve H. Antifungal agents: In vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 23: 256-270, 2004 Groll AH, Kolve H, Ehlert K, Paulussen M, Vormoor J. Pharmacokinetic interaction between voriconazole and ciclosporin A following bone marrow transplantation. J Antimicrob Chemother; 53: 113-114, 2004 Petraitis V, Petraitiene R, Kelaher AM, Sarafandi AA, Sein T, Mickiene D, Bacher J,Groll AH, Walsh TJ. Efficacy of PLD-118, a novel inhibitor of Candida Isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C.albicans. Antimicrob Agents Chemother; 48: 3959-3967, 2004 Petraitiene R, Petraitis V, Lyman C, Groll AH, Mickiene D, Bacher J, Roussillon M, Hemmings D, Armstrong D, Avila N, Walsh TJ. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole di-lysine phosphoester in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother: 48: 1188-1196, 2004 Shoan S, Groll AH, Walsh TJ. Antifungal agents. In Cohen J, Powderly W(eds): Infectious Diseases, 2nd ed. Mosby Publishers, Edinburgh, 2004: pp 1925-1940 Vormoor J, Ehlert K,Groll AH, Koch HG, Frosch M, Roth J. Successful hematopoietic stem cell transplantation in Farber Disease. J Pediatr 144: 132-134, 2004 Walsh TJ,Groll AH, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 Suppl.1: 48-66